GPI to present five pieces of research at ISPOR

GPI will be presenting five research posters at ISPOR, held in Copenhagen, Denmark from 12th – 15th November 2023.

Global Pricing Innovations is a market leader in price and market access insights, supporting pharma and biotech companies to maximise product value for patients through dynamic pricing and market access solutions.

We will be attending and presenting our research at ISPOR EU 2023 between 12th – 15th November 2023. Our representatives will be onsite and on hand to discuss how GPI can optimise your pricing and market access decision-making in 2023 and beyond. In addition, GPI will be presenting five research posters that will be available throughout the conference.

  • Can machine learning accurately predict payer behaviour?
  • Loss of Exclusivity (LoE): Impact analysis across Europe-5 and select Nordic countries
  • Predicting value and price of orphan drugs: a comparison across Europe and the US
  • Assessing the Barriers to Healthcare Resource Use (HRU) Data Collection and Offering Solutions to Support the Evidence Generation Process in LMICs
  • Predicting Drug Price Erosion in Germany Associated With Indication Expansion, to Understand the Potential Launch Price Benchmark for a New Product

ISPOR Research Posters

Can machine learning accurately predict payer behaviour?

As machine learning has gained popularity and excitement across many sectors, we investigated whether it could be applied to market access. In this research, we trained and tested the accuracy of machine learning models, when applied to our value-based pricing methodology, to determine the feasibility of predicting payer decisions and prices for a new orphan asset in France, Germany and the UK.

Date: 13th November at 10:30am; Poster session 1


 

Loss of Exclusivity (LoE): Impact analysis across Europe-5 and select Nordic countries

The financial impact of Loss of Exclusivity (LoE) on pharmaceutical companies can be significant and can vary depending on specific drug and market conditions. This research characterise the impact of LoE and company mitigation strategies in 8 European Countries; mainly Europe-5 and Denmark, Sweden, and Norway.​

Date: 15th November at 9am; Poster session 5


 

Predicting value and price of orphan drugs: a comparison across Europe and the US

Value-based pricing of pharmaceutical products has huge potential within market access and helps payers, pharmaceutical companies and patients by improving healthcare outcomes at an affordable cost. This research aims to determine the accuracy of a value-price model to forecast the price of an orphan product across different payer types; specifically, Italy, Spain and the US.​

Date: 15th November at 9am; Poster session 5


 

Assessing the Barriers to Healthcare Resource Use (HRU) Data Collection and Offering Solutions to Support the Evidence Generation Process in LMICs. ​​

Health care resource use (HRU) data is essential in understanding the budget impact of a product in a market. However, in many low- and middle-income countries sourcing such data remains difficult. This research sought to understand the key barriers in terms of collecting HRU data and potential solutions to overcome these.​

Date: 14th November at 15:30; Poster session 4​


 

Predicting Drug Price Erosion in Germany Associated With Indication Expansion, to Understand the Potential Launch Price Benchmark for a New Product.​​​

For countries which use price benchmarking, understanding the rate of price erosion for existing treatments is crucial to understand the likely launch price of a new product with no additional benefit. This research sought to understand the rate of and driving factors behind price erosion across several analogue products and use these to develop an algorithm to allow us to predict the new price of three treatments following indication expansion.​

Date: 15th November at 9am; Poster session 5



ISPOREU2023

Share the Article:

Sign up to our mailing list to be informed of the latest webinars